Author:
Birmingham Bruce K.,Swan Suzanne K.,Puchalski Tom,Mitchell Pat,Azumaya Connie,Zalikowski Julie,Wang Yi
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference41 articles.
1. US Renal Data System, USRDS 2011 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2011.
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(Suppl. 3):S112–9.
3. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002;61(1):297–304.
4. Mason NA, Bailie GR, Satayathum S, et al. HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in haemodialysis patients. Am J Kidney Dis. 2005;45(1):119–26.
5. Wanner C, Krane V, März W, et al. German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–48.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献